

Yanni Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1697117/publications.pdf>

Version: 2024-02-01

342
papers

13,646
citations

34016

52
h-index

34900

98
g-index

358
all docs

358
docs citations

358
times ranked

12616
citing authors

#	ARTICLE	IF	CITATIONS
1	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 779-789.	1.2	10
2	Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. <i>Hepatology</i> , 2023, 77, 65-76.	3.6	10
3	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 111-120.	2.0	11
4	Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Neuroendocrinology</i> , 2022, 112, 733-743.	1.2	3
5	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 1139-1149.	1.4	4
6	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	2.0	12
7	miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 360.	2.7	9
8	Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers. <i>Oncologist</i> , 2022, 27, 342-e383.	1.9	8
9	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	1.5	29
10	Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World. <i>Clinical Colorectal Cancer</i> , 2022, 21, e152-e161.	1.0	5
11	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. <i>Radiology</i> , 2022, 303, 455-464.	3.6	53
12	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, 279-279.	0.8	1
13	A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS222-TPS222.	0.8	0
14	A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 308-308.	0.8	9
15	First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 241-241.	0.8	13
16	Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II multicenter single-arm study and exploratory biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 301-301.	0.8	0
17	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 268-268.	0.8	1
18	LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS367-TPS367.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Abstract P5-16-04: Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific) Tj ETQq1 1 0.784314 rgBT /Over HER2-positive breast cancer: A phase II trial. <i>Cancer Research</i> , 2022, 82, P5-16-04-P5-16-04.	0.4	0
20	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	5.5	18
21	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. <i>JAMA Network Open</i> , 2022, 5, e224637.	2.8	6
22	Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. , 2022, 10, e004080.		33
23	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	13.7	156
24	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	7.7	3
25	Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. <i>BMC Cancer</i> , 2022, 22, 355.	1.1	2
26	Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 835389.	1.3	2
27	Paclitaxel and Cisplatin with or without Cetuximab in metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label Phase II trial. <i>Innovation(China)</i> , 2022, 3, 100239.	5.2	2
28	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	1.9	18
29	Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges. <i>Innovation(China)</i> , 2022, 3, 100249.	5.2	2
30	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3065-3076.	0.8	97
31	Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. <i>BMC Medicine</i> , 2022, 20, 133.	2.3	27
32	Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population. <i>EClinicalMedicine</i> , 2022, 47, 101394.	3.2	5
33	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. <i>BMJ, The</i> , 2022, 377, e068714.	3.0	133
34	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	15.2	190
35	Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). <i>European Journal of Cancer</i> , 2022, 169, 1-9.	1.3	5
36	Absence of <sc><i>NOTCH1</i></sc> mutation and presence of <sc><i>CDKN2A</i></sc> deletion predict progression of esophageal lesions. <i>Journal of Pathology</i> , 2022, 258, 38-48.	2.1	5

#	ARTICLE	IF	CITATIONS
37	Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211050.	1.4	8
38	A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4062-4062.	0.8	2
39	A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16264-e16264.	0.8	2
40	Prognostic and predictive impact of circulating tumor DNA in advanced gastric cancer treated with immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16019-e16019.	0.8	0
41	Genomic characterization of Chinese locally advanced or metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16085-e16085.	0.8	0
42	Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16107-e16107.	0.8	0
43	Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16102-e16102.	0.8	1
44	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16095-e16095.	0.8	0
45	A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4126-4126.	0.8	0
46	Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16191-e16191.	0.8	4
47	Abstract CT023: Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses. <i>Cancer Research</i> , 2022, 82, CT023-CT023.	0.4	5
48	Molecular profile of exosomal miRNA differential expression in ascites of untreated advanced gastric cancer patients with peritoneal metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16086-e16086.	0.8	0
49	Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4017-4017.	0.8	2
50	Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3591-3591.	0.8	0
51	Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9024-9024.	0.8	3
52	Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6563-6563.	0.8	0
53	First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4167-TPS4167.	0.8	1
54	FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15504-e15504.	0.8	1

#	ARTICLE	IF	CITATIONS
55	ChosenHRDw: A novel tool for the detection of homologous recombination deficiency(HRD) using low-pass whole-genome sequencing.. Journal of Clinical Oncology, 2022, 40, e17573-e17573.	0.8	0
56	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.. Journal of Clinical Oncology, 2022, 40, LBA4011-LBA4011.	0.8	18
57	Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.. Journal of Clinical Oncology, 2022, 40, 3100-3100.	0.8	9
58	A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 3000-3000.	0.8	0
59	A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 3089-3089.	0.8	11
60	A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, e15052-e15052.	0.8	3
61	Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.. Journal of Clinical Oncology, 2022, 40, 2568-2568.	0.8	6
62	Phase 1 study of C019199, an oral CSF-1R/DDR3/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including tenosynovial giant cell tumor.. Journal of Clinical Oncology, 2022, 40, TPS3177-TPS3177.	0.8	0
63	Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 161-175.	3.3	19
64	Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagus. Gastrointestinal Endoscopy, 2021, 93, 1065-1073.e3.	0.5	15
65	Advances on immune-related adverse events associated with immune checkpoint inhibitors. Frontiers of Medicine, 2021, 15, 33-42.	1.5	24
66	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1529-1536.	1.2	4
67	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164.	1.1	64
68	Ultrasensitive Gastric Cancer Circulating Tumor Cellular <i>CLDN18.2</i> RNA Detection Based on a Molecular Beacon. Analytical Chemistry, 2021, 93, 665-670.	3.2	22
69	Early change in peripheral CD4⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. Immunotherapy, 2021, 13, 55-66.	1.0	15
70	RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.. Journal of Clinical Oncology, 2021, 39, 199-199.	0.8	3
71	Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer in Clinical Practice, 2021, 19, 7.	0.6	4
72	Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report. Annals of Palliative Medicine, 2021, .	0.5	2

#	ARTICLE	IF	CITATIONS
73	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. Journal of Clinical Oncology, 2021, 39, 168-168.	0.8	5
74	Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinoma. Aging, 2021, 13, 6999-7019.	1.4	3
75	Determination of a novel photosensitizer sinoporphyrin sodium in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 195, 113852.	1.4	1
76	Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites. Journal of International Medical Research, 2021, 49, 030006052098666.	0.4	4
77	Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 748-756.	0.8	63
78	Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy. Nature Communications, 2021, 12, 2385.	5.8	25
79	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncology, 2021, 17, 1143-1153.	1.1	63
80	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the ARESO trial. Future Oncology, 2021, 17, 1923-1931.	1.1	2
81	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human anti-programmed death-1 monoclonal antibody for advanced solid tumors or lymphoma. European Journal of Cancer, 2021, 148, 1-13.	1.3	9
82	First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.. Journal of Clinical Oncology, 2021, 39, 4002-4002.	0.8	11
83	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. Npj Precision Oncology, 2021, 5, 36.	2.3	20
84	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer, 2021, 24, 913-925.	2.7	61
85	Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).. Journal of Clinical Oncology, 2021, 39, 4111-4111.	0.8	0
86	First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.. Journal of Clinical Oncology, 2021, 39, 4049-4049.	0.8	19
87	Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16040-e16040.	0.8	1
88	Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors. Future Oncology, 2021, 17, 1855-1863.	1.1	3
89	Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.. Journal of Clinical Oncology, 2021, 39, 3108-3108.	0.8	19
90	Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2503-2503.	0.8	13

#	ARTICLE	IF	CITATIONS
91	RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 4012-4012.	0.8	38
92	Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.. Journal of Clinical Oncology, 2021, 39, e14547-e14547.	0.8	1
93	A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients. Gastroenterology Report, 2021, 9, 339-349.	0.6	4
94	Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer. Human Cell, 2021, 34, 1446-1454.	1.2	7
95	Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications. Annals of Translational Medicine, 2021, 9, 967-967.	0.7	7
96	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, The, 2021, 398, 27-40.	6.3	1,237
97	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Frontiers in Oncology, 2021, 11, 589022.	1.3	20
98	Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Journal of Hematology and Oncology, 2021, 14, 95.	6.9	50
99	Glutathione-responsive PLGA nanocomplex for dual delivery of doxorubicin and curcumin to overcome tumor multidrug resistance. Nanomedicine, 2021, 16, 1411-1427.	1.7	5
100	Abstract LB126: Population and non-compartmental pharmacokinetic analysis of ripretinib and its active metabolite in Chinese patients with gastrointestinal stromal tumor. , 2021, , .		0
101	Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis. , 2021, , .		7
102	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	3.7	323
103	Proteomics provides individualized options of precision medicine for patients with gastric cancer. Science China Life Sciences, 2021, 64, 1199-1211.	2.3	8
104	The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ TÀcell dysfunction and tumor growth. Cancer Cell, 2021, 39, 945-957.e10.	7.7	124
105	Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncology. The, 2021, 22, 1081-1092.	5.1	178
106	Reply to M. A. Liu et al. Journal of Clinical Oncology, 2021, 39, 2519-2519.	0.8	0
107	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2021, 398, 759-771.	6.3	642
108	Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by <sc>HER2</sc> Status: A Noninterventional Registry Study (<sc>EVIDENCE</sc>). Oncologist, 2021, 26, e1567-e1580.	1.9	15

#	ARTICLE	IF	CITATIONS
109	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	1.0	1
110	The Inconsistent and Inadequate Reporting of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials. <i>Oncologist</i> , 2021, 26, e2239-e2246.	1.9	6
111	A validated HPLC-MS/MS method for determination of simmitemcan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. <i>Journal of Separation Science</i> , 2021, 44, 3959-3966.	1.3	2
112	Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein-Barr Virus Associated Gastric Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 611676.	1.3	3
113	Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646355.	1.3	27
114	Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. <i>Cancer Letters</i> , 2021, 517, 78-87.	3.2	14
115	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
116	Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 292-292.	0.8	7
117	Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1015-1024.	3.7	32
118	Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5175.	1.7	10
119	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. <i>Cancer Communications</i> , 2021, 41, 1173-1182.	3.7	77
120	Identification of coregulation of RhoA activity panel as a prognostic and predictive biomarker for gastric cancer. <i>Aging</i> , 2021, 13, 714-734.	1.4	1
121	Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?. <i>EBioMedicine</i> , 2021, 73, 103674.	2.7	7
122	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	1.3	5
123	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. <i>Genome Medicine</i> , 2021, 13, 175.	3.6	12
124	CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker. <i>American Journal of Cancer Research</i> , 2021, 11, 1697-1708.	1.4	0
125	Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab. <i>Journal of Clinical Oncology</i> , 2021, 9, A400-A400.		0
126	Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 754858.	1.6	2

#	ARTICLE	IF	CITATIONS
127	From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. <i>Frontiers in Pharmacology</i> , 2021, 12, 757994.	1.6	10
128	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	13.7	335
129	Development of an LC-MS/MS method for quantitative analysis of Chlorogenic acid in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112809.	1.4	10
130	Absence of Iodine Staining Associates With Progression of Esophageal Lesions in a Prospective Endoscopic Surveillance Study in China. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1626-1635.e7.	2.4	19
131	YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 329-342.	1.2	27
132	Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. <i>Gastric Cancer</i> , 2020, 23, 614-626.	2.7	23
133	Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 295-306.	1.0	11
134	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <sc>CONCUR</sc> trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	1.4	8
135	Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. <i>Cancer Communications</i> , 2020, 40, 746-751.	3.7	16
136	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Innovation(China)</i> , 2020, 1, 100041.	5.2	31
137	Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment. , 2020, 8, e001297.		25
138	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. , 2020, 8, e000374.		43
139	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. , 2020, 8, e000631.		22
140	Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. <i>Clinical and Translational Medicine</i> , 2020, 10, e148.	1.7	17
141	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568911.	1.3	17
142	Expert opinions on immunotherapy for patients with colorectal cancer. <i>Cancer Communications</i> , 2020, 40, 467-472.	3.7	18
143	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 1489-1499.	5.1	94
144	Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 1500-1512.	5.1	106

#	ARTICLE	IF	CITATIONS
145	The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1251-1261.	1.6	155
146	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	1.3	8
147	Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 12657-12666.	0.9	4
148	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 832-842.	5.1	350
149	Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	6.9	6
150	Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 3172-3180.	1.6	12
151	Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing. <i>Oncology</i> , 2020, 98, 583-588.	0.9	7
152	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
153	Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. <i>Science Advances</i> , 2020, 6, eaay4211.	4.7	60
154	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2020, 46, e33-e39.	0.5	24
155	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2337-2345.	3.2	66
156	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290.	13.7	213
157	Clinical trial analysis of 2019-nCoV therapy registered in China. <i>Journal of Medical Virology</i> , 2020, 92, 540-545.	2.5	120
158	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
159	Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. <i>Clinical Immunology</i> , 2020, 212, 108345.	1.4	18
160	Response to 'Comments on 'Zhang et al: Clinical trial analysis of 2019-nCoV therapy registered in China''. <i>Journal of Medical Virology</i> , 2020, 92, 713-713.	2.5	10
161	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 86, 102020.	3.4	9
162	Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. <i>Cancer</i> , 2020, 126, 2086-2092.	2.0	37

#	ARTICLE	IF	CITATIONS
163	<p>Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study</p>. <i>Clinical Pharmacology: Advances and Applications</i> , 2020, Volume 12, 21-33.	0.8	3
164	The current status of and prospects in research regarding gastrointestinal stromal tumors in China. <i>Cancer</i> , 2020, 126, 2048-2053.	2.0	11
165	Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. <i>Science</i> , 2020, 368, .	6.0	716
166	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	1.7	23
167	A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4560-4560.	0.8	23
168	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16001-e16001.	0.8	1
169	Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16551-e16551.	0.8	1
170	Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 334-334.	0.8	2
171	Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System. <i>Medical Science Monitor</i> , 2020, 26, e924671.	0.5	10
172	Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 263-270.	0.7	31
173	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 287-302.	0.7	20
174	MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15011-e15011.	0.8	1
175	Envafolelimab (KN035) in advanced tumors with mismatch-repair deficiency.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3021-3021.	0.8	3
176	Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3115-3115.	0.8	0
177	Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16014-e16014.	0.8	0
178	Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6047-6047.	0.8	0
179	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. <i>BMC Cancer</i> , 2019, 19, 705.	1.1	27
180	Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. <i>Cancer Medicine</i> , 2019, 8, 5000-5011.	1.3	11

#	ARTICLE	IF	CITATIONS
181	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. <i>Theranostics</i> , 2019, 9, 3485-3500.	4.6	9
182	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. <i>JAMA Network Open</i> , 2019, 2, e197621.	2.8	25
183	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	19
184	Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer. <i>IScience</i> , 2019, 22, 44-57.	1.9	16
185	Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 697.	2.7	18
186	Challenges in anticancer drug R&D in China. <i>Lancet Oncology</i> , The, 2019, 20, 183-186.	5.1	16
187	Voltage-dependent calcium channel α_1 subunit is a specific candidate marker for identifying gastric cancer stem cells. <i>Cancer Management and Research</i> , 2019, Volume 11, 4707-4718.	0.9	13
188	Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. <i>Cancer Medicine</i> , 2019, 8, 4766-4781.	1.3	201
189	Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 539-550.	1.1	7
190	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. <i>Clinical Colorectal Cancer</i> , 2019, 18, 175-182.	1.0	11
191	Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. <i>Cancer Letters</i> , 2019, 457, 142-150.	3.2	65
192	Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 225-230.	0.7	5
193	Nimotuzumab Plus Paclitaxel and Cisplatin as a 1 st -Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. <i>Journal of Cancer</i> , 2019, 10, 1409-1416.	1.2	12
194	Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. <i>Gastric Cancer</i> , 2019, 22, 1183-1192.	2.7	64
195	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
196	Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis. <i>Thoracic Cancer</i> , 2019, 10, 918-929.	0.8	6
197	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	1.4	16
198	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. <i>International Journal of Cancer</i> , 2019, 145, 2440-2449.	2.3	20

#	ARTICLE	IF	CITATIONS
199	Autophagy inhibition enhances PD-L1 expression in gastric cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 140.	3.5	104
200	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70</i>	6.9	69
201	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066.	1.1	132
202	Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 139.	2.7	16
203	Effects of <i>Helicobacter pylori</i> treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. <i>BMJ: British Medical Journal</i> , 2019, 366, l5016.	2.4	152
204	PRL-3 Promotes Ubiquitination and Degradation of AURKA and Colorectal Cancer Progression via Dephosphorylation of FZR1. <i>Cancer Research</i> , 2019, 79, 928-940.	0.4	25
205	Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. <i>Gut</i> , 2019, 68, 198-206.	6.1	89
206	S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4017-4017.	0.8	14
207	Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4025-4025.	0.8	3
208	Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4036-4036.	0.8	12
209	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4117-4117.	0.8	63
210	The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15516-e15516.	0.8	1
211	Nab-paclitaxel/S-1(AS) versus nab-paclitaxel/gemcitabine(AG) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A retrospective analysis of efficacy and safety.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15743-e15743.	0.8	1
212	Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 918-929.	0.7	9
213	Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines <i>via</i> regulating Shh-Gli1 signaling. <i>World Journal of Gastroenterology</i> , 2019, 25, 923-940.	1.4	10
214	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15012-e15012.	0.8	2
215	A multi-institutional investigation assessing prevalence of germline genetic alterations in Chinese patients with gastric carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13020-e13020.	0.8	0
216	A proteomic landscape of diffuse-type gastric cancer. <i>Nature Communications</i> , 2018, 9, 1012.	5.8	175

#	ARTICLE	IF	CITATIONS
217	A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. <i>Gastric Cancer</i> , 2018, 21, 782-791.	2.7	33
218	Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2018, 419, 64-74.	3.2	35
219	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. <i>Cell Death and Disease</i> , 2018, 9, 123.	2.7	76
220	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e233-e255.	1.0	26
221	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 20.	6.9	32
222	Management of gastrointestinal adverse events induced by immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
223	Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1399-1406.	1.9	31
224	Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. <i>Cancer Letters</i> , 2018, 412, 99-107.	3.2	69
225	Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. <i>World Journal of Gastroenterology</i> , 2018, 24, 266-273.	1.4	23
226	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-358.	0.8	160
227	Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer. <i>Cancer Communications</i> , 2018, 38, 1-3.	3.7	17
228	Noninvasive Detection of HER2 Expression in Gastric Cancer by ⁶⁴ Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. <i>Molecular Pharmaceutics</i> , 2018, 15, 5174-5182.	2.3	18
229	Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. <i>Journal of Hematology and Oncology</i> , 2018, 11, 109.	6.9	22
230	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1372-1384.	5.1	319
231	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	3.8	202
232	Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. <i>Cancer Medicine</i> , 2018, 7, 4361-4370.	1.3	11
233	A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 171.	1.8	25
234	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 129.	3.5	37

#	ARTICLE	IF	CITATIONS
235	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	18
236	Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 5261-5271.	3.2	42
237	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
238	Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. <i>Journal of Translational Medicine</i> , 2018, 16, 15.	1.8	29
239	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018, 14, 2031-2044.	1.1	20
240	Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 31-39.	0.8	8
241	MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study. <i>BMC Cancer</i> , 2018, 18, 811.	1.1	11
242	A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. <i>Cell Death and Disease</i> , 2018, 9, 661.	2.7	35
243	HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. <i>European Journal of Cancer</i> , 2018, 88, 92-100.	1.3	64
244	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3534-3534.	0.8	1
245	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3537-3537.	0.8	1
246	Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16059-e16059.	0.8	20
247	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	0.8	3
248	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 116-116.	0.8	9
249	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 747-747.	0.8	1
250	Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 553-563.	0.7	42
251	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-765.	0.8	9
252	Clinical characters and prognostic factors of young female patients (pts) with metastatic gastric adenocarcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 133-133.	0.8	0

#	ARTICLE	IF	CITATIONS
253	The pathway regulating RhoA activity to predict the survival of gastric cancers.. Journal of Clinical Oncology, 2018, 36, 49-49.	0.8	0
254	A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2018, 36, TPS3111-TPS3111.	0.8	0
255	Cost-effectiveness analysis of nivolumab and apatinib in third-line gastric cancer therapy.. Journal of Clinical Oncology, 2018, 36, e18931-e18931.	0.8	0
256	SPANOM: A cost-effective method of detecting MSI in ctDNA.. Journal of Clinical Oncology, 2018, 36, e24263-e24263.	0.8	0
257	Genomic profiling of early-onset metastatic Chinese colorectal cancer (mCRC) patients: The development of a PFS prediction model for first line treatments.. Journal of Clinical Oncology, 2018, 36, e15657-e15657.	0.8	0
258	miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil and. American Journal of Cancer Research, 2018, 8, 280-290.	1.4	11
259	Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial. International Journal of Cancer, 2017, 141, 837-847.	2.3	26
260	Association of serum uric acid with increased risk of cancer among hypertensive Chinese. International Journal of Cancer, 2017, 141, 112-120.	2.3	18
261	Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer. Translational Oncology, 2017, 10, 367-377.	1.7	12
262	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1637-1651.	5.1	233
263	Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Science, 2017, 108, 1881-1887.	1.7	51
264	Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors. Oncology and Therapy, 2017, 5, 171-180.	1.0	4
265	Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer, 2017, 17, 437.	1.1	21
266	CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. Journal of Translational Medicine, 2017, 15, 127.	1.8	45
267	Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma. Radiology, 2017, 283, 580-589.	3.6	36
268	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88.	1.0	19
269	Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study. Journal of the National Cancer Institute Monographs, 2017, 2017, .	0.9	38
270	Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis. Gastroenterology Research and Practice, 2017, 2017, 1-9.	0.7	6

#	ARTICLE	IF	CITATIONS
271	Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. <i>BMC Cancer</i> , 2017, 17, 521.	1.1	11
272	Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. <i>BMC Cancer</i> , 2017, 17, 885.	1.1	11
273	Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways. <i>Journal of Translational Medicine</i> , 2017, 15, 253.	1.8	11
274	Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. <i>Chinese Journal of Cancer</i> , 2017, 36, 81.	4.9	13
275	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017, 36, 97.	4.9	28
276	Peri/post-operative chemotherapy of oxaliplatin combined with S-1 (SOX) versus post-operative oxaliplatin with capecitabine (XELOX) in locally advanced gastric cancer: RESOLVE Trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15519-e15519.	0.8	1
277	Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma: Long term follow-up of survival in a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15573-e15573.	0.8	5
278	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 128-128.	0.8	7
279	Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. <i>Oncotarget</i> , 2017, 8, 42076-42086.	0.8	35
280	Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 281-293.	0.7	117
281	A phase I, open-label, nonrandomized, pharmacokinetic study of trifluridine/tipiracil (TAS-102) in Chinese patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14079-e14079.	0.8	0
282	Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing. <i>American Journal of Cancer Research</i> , 2017, 7, 1540-1553.	1.4	21
283	miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. <i>Oncotarget</i> , 2016, 7, 4817-4828.	0.8	54
284	Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. <i>PLoS ONE</i> , 2016, 11, e0156659.	1.1	25
285	Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>PLoS ONE</i> , 2016, 11, e0154679.	1.1	12
286	Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric cancer in Han Chinese with hereditary background. <i>Oncotarget</i> , 2016, 7, 33608-33615.	0.8	16
287	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
288	The patterns and timing of recurrence after curative resection for gastric cancer in China. <i>World Journal of Surgical Oncology</i> , 2016, 14, 305.	0.8	75

#	ARTICLE	IF	CITATIONS
289	Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. <i>Oncology Letters</i> , 2016, 12, 1763-1768.	0.8	9
290	Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. <i>Cancer Science</i> , 2016, 107, 486-490.	1.7	44
291	GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer. <i>Oncology Reports</i> , 2016, 36, 1672-1678.	1.2	11
292	The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. <i>Cancer Letters</i> , 2016, 380, 20-30.	3.2	20
293	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. <i>Human Pathology</i> , 2016, 55, 182-189.	1.1	58
294	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. <i>BMC Cancer</i> , 2016, 16, 68.	1.1	82
295	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
296	Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. <i>British Journal of Cancer</i> , 2016, 114, 138-145.	2.9	81
297	Reply to the letter by Takeshi Yamada et al. concerning "serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?" <i>Journal of Gastroenterology</i> , 2016, 51, 508-508.	2.3	0
298	Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 234-244.	2.7	90
299	A randomized, multicenter, controlled study to compare perioperative chemotherapy of oxaliplatin combined with TS-1 (SOX) versus SOX or oxaliplatin with capecitabine (XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection (RESOLVE Trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4136-TPS4136.	0.8	2
300	Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4139-TPS4139.	0.8	4
301	KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4140-TPS4140.	0.8	9
302	Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS189-TPS189.	0.8	3
303	Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. <i>Oncotarget</i> , 2016, 7, 50656-50665.	0.8	39
304	Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab. <i>Oncotarget</i> , 2016, 7, 75293-75306.	0.8	12
305	Intratatumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFR wild-type gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 30241-30249.	0.8	11
306	Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA <i>in situ</i> hybridization and its clinical significance. <i>Oncotarget</i> , 2016, 7, 39671-39679.	0.8	37

#	ARTICLE	IF	CITATIONS
307	Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 579-588.	0.7	22
308	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer, 2015, 15, 894.	1.1	27
309	Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment. Oncologist, 2015, 20, 619-620.	1.9	1
310	Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer, 2015, 15, 6.	1.1	27
311	Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560.	12.5	11
312	Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports, 2015, 5, 8542.	1.6	66
313	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 550-560.	5.1	96
314	Circulating <sc>PD</sc>L</sc>1 in <sc>NSCLC</sc> patients and the correlation between the level of <sc>PD</sc>L</sc>1 expression and the clinical characteristics. Thoracic Cancer, 2015, 6, 534-538.	0.8	107
315	Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. Carcinogenesis, 2015, 36, bgv147.	1.3	24
316	Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2015, 14, 2634-2641.	1.9	20
317	Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer, 2015, 18, 168-176.	2.7	209
318	HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 163-71.	0.7	23
319	Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis. PLoS ONE, 2014, 9, e84502.	1.1	80
320	Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study. Oncologist, 2014, 19, 1169-1178.	1.9	71
321	Detection of Epstein-Barr virus infection in cancer by using highly specific nanoprobe based on dBSA capped CdTe quantum dots. RSC Advances, 2014, 4, 22545.	1.7	9
322	Combination of microtubule associated protein-tau and β -tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. European Journal of Cancer, 2014, 50, 2328-2335.	1.3	24
323	Effects of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality in Subgroups. Journal of the National Cancer Institute, 2014, 106, .	3.0	121
324	Methylation Status of Blood Leukocyte DNA and Risk of Gastric Cancer in a High-Risk Chinese Population. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2019-2026.	1.1	10

#	ARTICLE	IF	CITATIONS
325	Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. <i>Oncotarget</i> , 2014, 5, 6594-6602.	0.8	69
326	Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 3356.	1.4	1
327	A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 141-141.	0.8	0
328	A phase II study of sequential Irinotecan plus cisplatin (IP) and octreotide LAR as first-line treatment of metastatic or inoperable poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15156-e15156.	0.8	0
329	First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2615-2615.	0.8	0
330	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4070-4070.	0.8	0
331	A comparative study between Embosphere(®) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 124-31.	0.7	10
332	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e535-e547.	5.1	418
333	A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 153.	0.3	5
334	Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10501-10501.	0.8	8
335	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4097-4097.	0.8	2
336	Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4150-TPS4150.	0.8	16
337	Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14644-e14644.	0.8	0
338	Efficacy of paclitaxel plus cisplatin in advanced esophageal squamous cell cancer: Further analysis of single center, prospective study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15174-e15174.	0.8	1
339	Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 291-298.	0.7	13
340	Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4081-4081.	0.8	0
341	Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14604-e14604.	0.8	0
342	Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 400-403.	0.1	1